Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NLSP | US
-0.54
-10.19%
Healthcare
Biotechnology
31/03/2024
21/10/2024
4.76
5.20
5.40
4.52
NLS Pharmaceutics AG a clinical-stage biopharmaceutical company engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy idiopathic hypersomnia and other rare sleep disorders as well as neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4 a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3 a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8 a melatonin ML1A receptor agonist improved scopolamine-induced amnesia; NLS-11 a norepinephrine and dopamine reuptake inhibitor and muscarinic M1 M2 M3 receptor antagonist; and NLS-12 a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich Switzerland.
View LessLow Debt to Equity (< 0.25)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
114.5%1 month
97.3%3 months
92.7%6 months
166.2%-
-
4.84
-0.18
0.88
-3.02
-
-
-11.80M
11.77M
11.77M
-
-
-
-
-862.92
1.70
5.33
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.54
Range1M
5.83
Range3M
5.83
Rel. volume
1.47
Price X volume
245.92K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Edesa Biotech Inc | EDSA | Biotechnology | 3.8235 | 12.42M | -5.83% | n/a | 1.35% |
Immuron Limited | IMRN | Biotechnology | 1.96 | 11.90M | 2.62% | n/a | 1.37% |
VINC | VINC | Biotechnology | 0.3781 | 11.68M | -0.50% | n/a | 12.51% |
Brainstorm Cell Therapeutics Inc | BCLI | Biotechnology | 2.19 | 11.64M | -2.67% | n/a | -27.28% |
BioRestorative Therapies Inc | BRTX | Biotechnology | 1.6779 | 11.61M | 0.77% | n/a | 0.77% |
DOMH | DOMH | Biotechnology | 1.82 | 11.42M | 0.55% | n/a | 7.66% |
RedHill Biopharma Ltd | RDHL | Biotechnology | 8.62 | 11.04M | -1.88% | n/a | 65.80% |
Common Stock | ADXN | Biotechnology | 10.3 | 11.01M | -1.34% | n/a | 0.25% |
Mustang Bio Inc | MBIO | Biotechnology | 0.2935 | 10.93M | 35.00% | n/a | -13.03% |
Jaguar Health Inc | JAGX | Biotechnology | 1.18 | 10.90M | -3.28% | 0.25 | 176.14% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.02 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 4.84 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 92.69 | 72.80 | Riskier |
Debt to Equity | -0.18 | -1.23 | Expensive |
Debt to Assets | 0.88 | 0.25 | Expensive |
Market Cap | 11.77M | 3.66B | Emerging |